Hinova Pharma, a novel drug developer based in southwestern China’s Chengdu city, announced on Monday the completion of a US$40 million series B round of financing led by healthcare-focused private equity fund Hermed Capital and Chinese listed pharmaceutical firm Fosun Pharma.
Chinese Novel Drug Developer Hinova Pharma Nets $40M In Series B Round comes originally from Continue Reading the Entire Article Here >>
